Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “C...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-10-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | https://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| _version_ | 1818900713447620608 |
|---|---|
| author | Shiferaw D Faruqi S |
| author_facet | Shiferaw D Faruqi S |
| author_sort | Shiferaw D |
| collection | DOAJ |
| description | Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1”Read the original article |
| first_indexed | 2024-12-19T20:08:14Z |
| format | Article |
| id | doaj.art-5afe37f0728b4e64a8ea824f8117b0de |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-19T20:08:14Z |
| publishDate | 2019-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-5afe37f0728b4e64a8ea824f8117b0de2022-12-21T20:07:24ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2019-10-01Volume 151207120849082Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]Shiferaw DFaruqi SShiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1”Read the original articlehttps://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| spellingShingle | Shiferaw D Faruqi S Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] Therapeutics and Clinical Risk Management |
| title | Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_full | Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_fullStr | Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_full_unstemmed | Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_short | Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum] |
| title_sort | profile of tezacaftor ivacaftor combination and its potential in the treatment of cystic fibrosis erratum |
| url | https://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT shiferawd profileoftezacaftorivacaftorcombinationanditspotentialinthetreatmentofcysticfibrosiserratum AT faruqis profileoftezacaftorivacaftorcombinationanditspotentialinthetreatmentofcysticfibrosiserratum |